GlassScriptPhysician profile
Josh L Werber
NPI 1083610455
$6,604.42
in general payments reported to CMS, 2019-2025
14 companies · $990 in 2025
The $990 reported for 2025 was more than what 79% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $593 · 2021: $533 · 2022: $1,204 · 2023: $1,503 · 2024: $1,270 · 2025: $990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,707 · Education: $56.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,707.21 |
| Education | $56.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,655.63 | 2020-2025 | |
| Inspire Medical Systems, INC. | $1,269.42 | 2020-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $894.14 | 2020-2025 | Dupixent |
| Glaxosmithkline, LLC. | $856.13 | 2021-2025 | Nucala |
| Optinose US, INC. | $760.99 | 2019-2025 | |
| Stryker Corporation | $343.73 | 2019-2021 | |
| Neurent Medical Limited | $230.49 | 2023 | Neuromark Radiofrequency Console, Neuromark Device |
| Aerin Medical INC. | $200.38 | 2022-2023 | |
| Acclarent, INC | $122.18 | 2019-2024 | Acclarent Aera |
| Intersect Ent, INC. | $89.66 | 2019-2020 | |
| Arrinex, INC. | $82.85 | 2019 | |
| Medtronic, INC. | $58.33 | 2023 | V-Loc 180 |
| Lilly USA, LLC | $27.49 | 2025 | Zepbound, Mounjaro |
| Glenmark Therapeutics INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josh Werber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.